ReviewTherapeutic advances in endocrinology and metabolism2024
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.
Review in Therapeutic advances in endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study.Lipids in health and disease · 2025Trial
- A TyG-UHR-based machine learning model for screening lean MAFLD: development and external validation.Biomedical engineering online · 2026Article
- Differential DNAm-GDF15 and mitochondrial profile in lean MAFLD.Clinical and experimental medicine · 2026Article
- What is new in the 2025 APASL guidelines for metabolic dysfunction-associated fatty liver disease?Hepatobiliary surgery and nutrition · 2026Article
- Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- Association between triglyceride glucose-body mass index and MASH, cardiovascular disease in MASLD patients: a cross-sectional study and machine learning analysis.Metabolism open · 2025Article
- Joint association of inflammatory markers and sedentary time with mortality in metabolic dysfunction-associated steatotic liver disease population and the mediating role of inflammation.European journal of medical research · 2025Article
- Genetic insights of waist-to-height ratio on the risk of steatotic and advanced liver diseases: genome-wide association study and polygenic risk score-based analyses.Human genomics · 2025Article
- Review
- Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status.Scientific reports · 2025Article
- Utility of the serum alanine aminotransferase to high density lipoprotein cholesterol ratio in evaluating nonalcoholic fatty liver disease and liver fibrosis.Scientific reports · 2025Article
- The burden of metabolic diseases in the Arab region, 1990-2021.Therapeutic advances in endocrinology and metabolism · 2025Article
- MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.Hepatic medicine : evidence and research · 2025Review
- Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is significant, impacting almost one-third of the global population. MAFLD constitutes a primary cause of end-stage liver disease, liver cancer and the need for liver transplantation. Moreover, it has a strong association with increased mortality rates due to various extrahepatic complications, notably cardiometabolic diseases. While MAFLD is typically correlated with obesity, not all individuals with obesity develop the disease and a significant percentage of MAFLD occurs in patients without obesity, termed lean MAFLD. The clinical features, progression and underlying physiological mechanisms of patients with lean MAFLD remain inadequately characterized. The present review aims to provide a comprehensive summary of current knowledge on lean MAFLD and offer a perspective on defining MAFLD in individuals with normal weight. Key to this process is the concept of metabolic health and flexibility, which links states of dysmetabolism to the development of lean MAFLD. This perspective offers a more nuanced understanding of MAFLD and its underlying mechanisms and highlights the importance of considering the broader metabolic context in which the disease occurs. It also bridges the knowledge gap and offers insights that can inform clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.